Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína4. fázis

Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets

A legfontosabb adatok

Ki végzi
Huashan Hospital
Hol
Shanghai (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
4. fázis
Résztvevők
312 fő, tervezett
Kezdés
2024. ápr. 10.
Tervezett befejezés
2026. ápr. 30.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Sodium Bicarbonate Oral Capsule
  • Potassium Citrate Tablets
  • uric-acid-lowering drug
A regiszteradat frissítve
2025. május 13.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with gout who already take a stable uric acid-lowering drug. It tests if potassium citrate or sodium bicarbonate added to this treatment lowers uric acid, gout flares and kidney stones.

Életkor
18 to 70 years
Nem
All sexes can join.
A betegség stádiuma
Gout diagnosed by the 2015 ACR/EULAR criteria. The last gout attack must be more than 2 weeks ago. People with a gout flare right now cannot join.
Korábbi kezelés
A stable dose of uric acid-lowering drugs for more than 4 weeks (for example febuxostat, allopurinol or benzbromarone).
Biomarker vagy leletérték
Urine pH must not be above 6.5 at screening.

A részvétel fő kizáró okai

  • Gout caused by another disease, by certain drugs, or by tumor radiotherapy or chemotherapy
  • Poor kidney function (eGFR≤60ml/min/1.73m^2) or high blood potassium
  • Severe unstable heart or brain blood vessel disease, or uncontrolled high blood pressure or diabetes
  • Liver disease or ALT or AST≥2 times the upper limit of normal
  • Pregnancy, planning a pregnancy, or breastfeeding

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Meet the diagnostic criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) for gout in 2015
  • Age 18-70 years old, gender is not limited
  • The interval between the most recent acute onset of gout is at least > 2 weeks
  • Routine treatment with stable dose of uric-lowering drugs for > 4 weeks
  • For women who are likely to become pregnant, pregnancy tests must be negative, they must not be lactating, they must be using an investigator-approved method of contraception, and they must agree to maintain this method of contraception throughout the study
  • Study participants were informed, voluntarily signed informed consent, and agreed to participate in all visits, examinations, and treatments as required by the trial protocol
  • Informed consent to the purpose and content of the research

Ki nem vehet részt

  • Secondary gout caused by kidney disease, blood disease, or taking certain drugs, tumor radiotherapy and chemotherapy
  • Active peptic ulcer or ulcer with bleeding and perforation, severe chronic diarrhea or recurrent skin disease in the past year
  • Women who are pregnant, planning to become pregnant or breastfeeding mental illness, no self-knowledge, unable to accurately express or can not take drugs on time
  • A history of alcohol abuse or dependence on known drugs within the last two years
  • Other lesions or conditions that, in the investigator's judgment, reduce or complicate enrollment
  • Severe and unstable cardiovascular and cerebrovascular diseases (such as unstable angina pectoris, coronary angiogenesis, cerebral angiogenesis, transient ischemic attack, congestive heart failure, etc.), acute and difficult to control diseases, chronic diffuse connective tissue disease, xanthine urethral deposition, Lesch-Nyhan syndrome, untreated thyroid disease or kidney stones, treatment Patients with severe hypertension (blood pressure > 160/100mmHg) or diabetes (fasting blood glucose > 11.1mmol/L) and organ transplantation that were not effectively controlled later
  • People who are allergic, have a history of allergy to test-related drugs (febuxosita tablets, allopurinol tablets, benzbromarone, etoracoxib, colchicine, potassium citrate, etc.) or are allergic to test-related drug components
  • Blood white blood cell count < 3.0x109/L, hemoglobin < 90g/L, platelet count < 100x109/L, or other blood system diseases (such as severe anemia, idiopathic thrombocytopenic purpura, spleen enlargement, coagulation dysfunction, etc.)
  • Active stage of liver disease or abnormal liver function (ALT or AST≥2 times the upper limit of normal)
  • Patients with abnormal renal function (eGFR≤60ml/min/1.73m\^2)
  • Patients with elevated blood potassium (5.5mmol/L) may have diseases or factors that may lead to hyperkalemia, such as type IV renal tubular acidosis and widespread tissue injury
  • Combined use of the following drugs: Contains salicylate drugs such as aspirin (> 300mg/d), thiazide diuretics, potassium diuretics such as amphenopterine, Amiloride, ACEI, azathioprine, 6-mercaptopurine, theophylline, losartan, cyclosporin A, cyclophospfamide, pyrazinamide, glucocorticoid (except in acute episodes), Niergoline tablets, long-term use of insulin, Digitalis
  • Acute gout flare
  • Urine PH value > 6.5 during screening
  • Those who have participated or are participating in other clinical trials within three months
  • The study participant is a family member or relative of the staff of the research Center

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 70 év között vagy?

Helyszínek itt: Kína

  • Huashan Hospital, Fudan UniversityShanghai, KínaContact: Yu MiaoRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate whether alkalization has the effect of lowering uric acid and reducing gout flare and determine whether alkalization has a role in the prevention and treatment of urinary calculi in gout, the research participants were divided into the control group, the potassium citrate group and the sodium bicarbonate group. 2 alkalization groups took potassium citrate three times a day 2.16g each time, or sodium bicarbonate three times a day, 1.0g each time, on the basis of the standard uric acid-lowering treatment plan. The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable.

A vizsgálat 3 csoportja

  • Controll groupMár használt kezelés, összehasonlításként

    The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone.

    Kezelés: uric-acid-lowering drug

  • Potassium citrate groupA vizsgált kezelés

    On the basis of the standard uric acid-lowering treatment plan, potassium citrate was taken three times a day, 2.16g each time.

    Kezelés: Potassium Citrate Tablets és uric-acid-lowering drug

  • Sodium bicarbonate groupA vizsgált kezelés

    Sodium Bicarbonate Oral Capsule

    Kezelés: Sodium Bicarbonate Oral Capsule és uric-acid-lowering drug

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06966635: ki vehet részt
A regiszteradat frissítve
2025. május 13.